For sublingual (SL) immunotherapy, what is required for the first dose?

For sublingual immunotherapy, the first dose must be administered in a doctor's office. This requirement is in place to ensure the safety and monitoring of the patient during the initial exposure to the allergen. During the first dose, there is a risk of an allergic reaction, including potentially serious events like anaphylaxis.

By administering the first dose in a controlled medical environment, healthcare professionals can observe the patient for any immediate adverse reactions and provide prompt treatment if necessary. This careful monitoring helps ensure that the patient is stable before they begin administering the therapy at home, thereby adding an important layer of safety.

The subsequent doses can be taken outside of a medical facility, but the initial dose is crucial to establish tolerance to the allergens in a safe setting.